290results about "Ether/acetal active ingredients" patented technology

The invention belongs to the technical field of pharmaceutical preparations, and relates to traditional Chinese medicine self-assembled nanoparticles for enhancing anti-inflammatory activity as well as a preparation method and application of the traditional Chinese medicine self-assembled nanoparticles. The traditional Chinese medicine self-assembled nanoparticles are prepared from biphenyl cyclooctene type lignan and an oleanane type pentacyclic triterpenoid compound, wherein the mass ratio of the biphenyl cyclooctene type lignan to the oleanane type pentacyclic triterpenoid compound is 1 to (0.125 to 8). Through an anti-solvent exchange method, the carrier-free nanoparticles based on self-assembly of the traditional Chinese medicine active ingredients are prepared by utilizing spontaneous non-covalent interaction between the biphenyl cyclooctene lignan and the oleanane pentacyclic triterpenoid, so that the cytotoxicity is remarkably reduced, the biocompatibility is enhanced, and the toxic and side effects are reduced; meanwhile, the traditional Chinese medicine self-assembled nano-particles have a remarkable cellular uptake effect, the absorption and utilization efficiency of the medicine is improved, and more efficient anti-inflammatory biological activity is shown.

Novel compositions and systems for closure of wounds with antimicrobial effectiveness provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. A novel platinum catalyst comprising platinum tetramethyldivinyl disiloxane diethyl maleate complex for use in such compositions provides for rapid curing on topical surfaces such as skin and bonds to such surfaces in about 2-5 minutes.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

The invention relates to the technical field of functional antioxidants, in particular to a stability-enhanced antioxidant based on pterostilbene and a preparation method and application thereof. The pterostilbene tablet comprises the following components in percentage by weight: 10-30% of pterostilbene, 8-20% of Arabic gum, 5-15% of tocopheryl succinate, 1-5% of disodium ethylene diamine tetraacetate, 30-60% of beta-cyclodextrin, 2-8% of rosmarinic acid, 1-6% of chitosan quaternary ammonium salt, 0.5-3% of nano silicon dioxide and 2-7% of polyglycerol fatty acid ester. In the preparation process, beta-cyclodextrin and pterostilbene form an inclusion compound, the dispersity of nano silicon dioxide and chitosan quaternary ammonium salt is improved through hydrogen bonds, and tea polyphenol or ascorbyl palmitate can be added to enhance the synergistic effect. The antioxidant is high in stability, high in pterostilbene retention rate, uniform in dispersion, free of agglomeration, excellent in antioxidant activity, suitable for the fields of foods, cosmetics and medicines, simple in preparation process, low in consumption and suitable for industrial production.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

A flowpack for oral delivery of active ingredients comprises a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein at least one of said two types of sugar alcohol particles comprises granulated sugar alcohol particles.

The present disclosure provides for the use of compounds of Formula I in lipid micro- and nanoparticle compositions. The present disclosure also extends to micro- or nanoparticles comprising a compound of Formula I and an optional payload molecule, and medical uses thereof.

The invention provides a phenoxy (hetero) aryl ether with anti-proliferative activity. The invention of the present application includes novel aromatic molecules useful in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders, such as disorders of the hematopoietic system, including the blood system, in human and veterinary medicine.

The application discloses a kind of miraculin compounds and its extraction method and application, belong to the field of traditional Chinese medicine extraction, specifically related to a kind of miraculin compounds as shown in general formula (I) and (II) isolated from Rhododendron dauricum and the extraction method of the compound, and the compound or the isomer of the compound, or the inhibitory effect of the compound on inflammation in pharmaceutically acceptable salt or pharmaceutical composition comprising the compound can be used for preparing anti-inflammatory drugs.The application further enriches the structural diversity of active substances of Rhododendron dauricum, which lays a foundation for subsequent related biological activity tests of monomeric compounds, provides active lead compounds for new drug development, and also provides a theoretical basis for in-depth research and development of Rhododendron dauricum medicinal materials.

The invention relates to a composition based on a natural lignocellulose complex, a source of dietary fiber exhibiting antioxidant and adsorption properties and dihydromyrecitin or quercetin, which ha

The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and / or pterostilbene - Pomegranate extract and / or - Sulforaphane or a source of sulforaphane; and - Vitamin D.

The invention discloses a composition capable of improving oral bioavailability of drugs and a method thereof, and further discloses application of a delivery synergist in improving the oral bioavailability of protein or polypeptide drugs. After the delivery synergist is added into the pharmaceutical composition, the delivery effect of a delivery agent can be exerted to the maximum extent under a certain proportion of the delivery synergist and the delivery agent, the use amount of the delivery agent can be reduced, and meanwhile the oral bioavailability of the medicine can be improved.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

A method for preparing a foamed sclerosant composition. One method includes introducing a liquid sclerosant composition into a foaming space of an interior of a container, the foaming space containing a mixing component having a magnetic part. Rotation of the mixing component is achieved by generating for a first holding time a rotating magnetic field at a first speed and after the first holding time generating for a second holding time the rotating magnetic field at a second speed greater than the first speed.

The present invention relates to obesity control by regulating the expression level of TREK1.

1 / Topical composition, advantageously ecobiological, comprising i). at least one compound of general formula (I) or one of its salts, said formula being ii). at least one compound of general formula (IIA) or one of its salts, or of general formula (IIB) or one of its salts, and their mixture: And use to protect the skin, mucous membranes, hair and / or scalp against UV radiation.

The present invention relates to an AMPK activator comprising 1,1-diethoxyethane as an active ingredient, and uses thereof. More specifically, the present invention relates to an AMPK activator comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient, and uses thereof, for example, as a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, which is a composition for preventing, treating, or alleviating diseases requiring AMPK activation, and for anti-aging, lifespan extension, or physical vitality enhancement.

The present application relates to a kind of bone repair compositions and its preparation method, belong to biological medicine technical field, pharmaceutical composition includes acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide, yak bone peptide, loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract;Acid anhydride bovine beta-lactoglobulin peptide is prepared using special enzymolysis method.Acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide and yak bone peptide are loaded using carboxymethyl chitosan-hydroxyapatite composite microspheres, then using sodium alginate-sodium carboxymethyl cellulose containing loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract one coating, then using sodium alginate-sodium carboxymethyl cellulose secondary coating.The present application develops high-efficiency pharmaceutical combination component, using polymer material to coat drug to form sustained-release system, improve bioavailability, using granular carrier to increase the stability and solubility of drug, promote intestinal absorption, improve bone repair process.

The present invention provides a reduced coenzyme Q10 crystal which, when measured by means of differential scanning calorimetry at a heating rate of 10 k / min, exhibits an endothermic peak at 52±2°C. Compared with the prior art, the crystal form of reduced coenzyme Q10 provided by the present invention is more stable than reduced coenzyme Q10 crystals reported in the literature, and other physical properties, including water solubility and residual solvents, are also superior; in addition, the crystal form provided by the present invention also overcomes the disadvantages of previously known reduced coenzyme Q10, which is very easily oxidized and has limitations in use; furthermore, the reduced coenzyme Q10 crystal and a crystalline solid containing the crystal provided by the present invention not only have excellent physical properties in terms of stability, but also stand out in terms of high purity and low solvent residue.

The present invention discloses compounds of general formula I for use in the treatment and prevention of COVID-19 in human subjects, in particular for inhibiting SARS-CoV-2: [Formula 1] JPEG2024514770000008.jpg5390 (wherein R1 to R6 are the same or different and are H, OH-, or OR7, R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are other than H).

The present invention provides compounds that are useful as modulators of the cannabinoid receptor 2 (CB2R) having the general formula (I), wherein R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

To provide SARS-CoV-2 inactivating agents showing excellent SARS-CoV-2 inactivating effect.SOLUTION: Provided is a SARS-CoV-2 inactivating agent containing a polyoxyethylene alkyl ether having an alkyl group with 12 carbon atoms and an average molar addition number of ethylene oxide of 8 or less, as an active ingredient, the concentration of the polyoxyethylene alkyl ether being 150 ppm or more and less than 2000 ppm.SELECTED DRAWING: None

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-CoV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS CoV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

The present disclosure provides acaricidal compounds, i.e. compounds 3c {3,6}, 3c {4,6}, 3c {3, 3}, 3c{4,3}and 3c {6,6}, that are effective in killing Varroa destructor mites while being harmless to honey bees.

Therapeutic liquid compositions useful in the treatment of various conditions comprising a natural bulk sweetener that has a low fructose content.